文献速递临床试验与 GCP基础与转化研究

苓桂术甘汤治疗脾阳虚型非酒精性脂肪肝的多中心随机对照试验方案

Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2020-06-10

本研究为三臂、剂量优化、随机双盲安慰剂对照临床试验,计划纳入243例脾阳虚型非酒精性脂肪肝患者,按1:1:1随机分配至标准剂量苓桂术甘汤组、低剂量组或安慰剂组,治疗12周随访4周。主要结局为12周时HOMA-IR较基线下降至少1个单位的受试者比例,旨在初步评价苓桂术甘汤的有效性与安全性。

要点

  • 苓桂术甘汤治疗脾阳虚型NAFLD尚缺乏严格临床试验证据。
  • 主要结局为12周HOMA-IR下降≥1单位的受试者比例。
  • 试验采用三臂、双盲、安慰剂对照及剂量优化设计。

核心结论

  • 本研究旨在提供苓桂术甘汤治疗脾阳虚型非酒精性脂肪肝有效性与安全性的初步证据。

研究设计与样本

  • 三臂、剂量优化、随机、双盲、安慰剂对照临床试验。
  • 计划招募243例非酒精性脂肪肝患者,按1:1:1随机分配至标准剂量苓桂术甘汤组、低剂量苓桂术甘汤组或安慰剂组。
  • 治疗期12周,随访期4周。

关键数值与推荐

  • 主要结局为从基线至12周HOMA-IR下降至少1个单位的受试者比例。
  • 次要结局包括体重、体质指数、肝功能、血脂代谢、血糖代谢、炎症反应、超声肝肾回声比及多种量表的变化。

临床怎么用

  • 若试验证实有效,可促进苓桂术甘汤在社区医疗中心的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease characterized by excessive fat accumulation in the liver. One of the underlying pathophysiological mechanisms is insulin resistance (IR). Traditional Chinese medicine (TCM) has showed potential benefits in the management of NAFLD. Lingguizhugan decoction (LGZG) is a representative Chinese herbal formula; however, there is still no rigorous clinical trial supporting its application. METHODS/DESIGN: This study will be a three-arm, dose-optimization, randomized, double-blinded, placebo-controlled clinical trial. A total of 243 patients with NAFLD will be recruited and randomly assigned to the standard dose LGZG (SLGD) group, low dose LGZG (LLGD) group, or the placebo group based on a ratio of 1:1:1. The treatment period will be 12 weeks and the follow-up period will last 4 weeks. The primary outcome will be the proportions of participants with at least a 1-unit decrease of HOMA-IR from baseline to 12 weeks. Secondary outcomes will include the changes of body weight, body mass index, liver function, blood lipid metabolism, blood glucose metabolism, inflammatory responses, liver-kidney echo ratio by ultrasound, and various scales. Biological samples will also be collected for future researches on mechanism exploration. DISCUSSION: This study will provide initial evidence regarding the efficacy and safety of LGZG in the treatment of NAFLD with spleen-yang deficiency pattern and promote its application in community healthcare centers. In addition, potential mechanisms will be explored based on studies of oral and gut microbiota. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800014364. Registered on 1 January 2018. The final protocol version was V3.0.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xu J, Wang R, You S, et al. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial. Trials. 2020. PMID: 32522273. doi:10.1186/s13063-020-04362-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。